The global ulcerated necrosis lipoidica management market sales is expected to reach a remarkable valuation of US$ 4.4 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.03 percent to reach US$ 7.9 billion by 2033. Over the projected period, the market for necrotizing skin infection treatments is anticipated to rise as a result of the increasing use of improved diagnostic techniques, such as magnetic resonance imaging, for the diagnosis of necrobiosis lipoidica. The approval and introduction of novel medications by top businesses is another important aspect driving the global market for ulcerated necrobiosis lipoidica management.
The adoption of PUVA therapy and Photodynamic therapy are two most common treatment options for treatment of Ulcerated Necrobiosis Lipoidica which is expected to propel market growth during the forecast period. In the coming years, the market is anticipated to be driven by key developments in drug development and growing number of drugs in clinical trials, as well as more inclination towards biological and technological advances.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16601
On the other hand, increasing economic burden of Ulcerated necrobiosis including direct and indirect cost of treatment, along with prolonged treatment duration and dearth of clinically proven drugs has presented significant unmet needs in the global Ulcerated necrobiosis lipoidica treatment market growth. This is providing vast opportunities for key players in this market by developing new drugs against necrobiosis lipoidica, with the aim to fight the resistant bacteria thus lowering the cost of treatment.
Likewise, product approvals by regulatory authorities are also anticipated to drive growth of the Ulcerated Necrobiosis Lipoidica Management market during the forecast period. For example, on June 19, 2017, Melinta Therapeutics which is a pharmaceutical company, declared that its product Baxdela (delafloxacin), was approved from the United States Food and Drug Administrator, which is used in the treatment of severe bacterial skin structure infections caused by vulnerable bacteria. This product is a ‘fluoroquinolone’ that shows activity against both gram-positive and gram-negative bacteria, and against methicillin-resistant Staphylococcus aureus. These developments will further propel market growth.
Key Takeaways
- North America is expected to dominate the industry while reaching market share of around 41% by end of the forecast period.
- The market in Asia Pacific is projected to account for 32.8% market share by end of the projected period.
- By treatment type, ‘UVA1 Phototherapy’ is projected to account for 31% market share by end of the forecast period.
- Hospitals are expected to dominate the market by distribution channel, with a market share of 71% by 2033.
Development of new clinically proven and effective drugs coupled with increasing healthcare expenditure is going to drive the treat market of Ulcerated necrobiosis lipoidica in the forecast period- Comments an FMI Analyst
Competitive Landscape
The Ulcerated Necrobiosis Lipoidica Management Market is intensely competitive and consists of numerous key market players. These key players are developing novel delivery systems for treating ulcerated necrobiosis lipoidica. This is estimated to fuel Ulcerated Necrobiosis Lipoidica Management Market. The key players in this market are: Astellas Pharma, Vibcare Pharma, Pfizer, Manus Aktteva Biopharma LLP, Mylan Pharmaceuticals Inc., Upsher-Smith Laboratories, Novartis, Sanofi, Merck, GlaxoSmithKline.
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Ulcerated Necrobiosis Lipoidica Management Market.
- In June 2022, Basilea Pharmaceutica Ltd declared positive topline results for the Phase III ERADICATE study, evaluating ceftobiprole in treating adult patients with bacterial bloodstream infections caused by Staphylococcus aureus.
- In January 2022, Paladin Labs Inc., which is a subsidiary of Endo International PLC announced the launch of ‘Xydalba’ (dalbavancin for injection), a 30-minute intravenous therapy for chronic bacterial skin structure infections that can be administered as a single- or two-dose.
- On July 7, 2021, Melinta Therapeutics, a pharmaceutical company, announced about launch of its product ‘KIMYRSA’. This drug is a lipoglycopeptide antibiotic that offers a complete course of treatment for chronic bacterial skin and skin structure infections including ulcerated necrobiosis lipoidica. This drug is effective in a single dose of 1200mg injection.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Ulcerated Necrobiosis Lipoidica Management Market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
To understand opportunities in the Ulcerated Necrobiosis Lipoidica Management Market the market is segmented on the basis of treatment ( Skin Grafting , Photodynamic Therapy , UVA1 Phototherapy, Topical Psoralen-UVA Therapy, Drugs-Antimalarial Agents, Antitubercular Agents, Immunosuppressive Agents, Hemorrheologic Agents, Fumaric Acid Esters, Calcineurin Inhibitors, Corticosteroids)(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Key Segments Profiled in the Ulcerated Necrobiosis Lipoidica Management Industry Survey
By Treatment:
- Skin Grafting
- Photodynamic Therapy
- UVA1 Phototherapy
- Topical Psoralen-UVA Therapy
- Drugs
- Antimalarial Agents
- Antitubercular Agents
- Immunosuppressive Agents
- Hemorrheologic Agents
- Fumaric Acid Esters
- Calcineurin Inhibitors
- Corticosteroids
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-16601
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube